Virginia Commonwealth University

VCU Scholars Compass
Medicinal Chemistry Publications

Dept. of Medicinal Chemistry

2012

Design, Synthesis, and In Vitro and In Vivo
Biological Studies of a 3′-Deoxythymidine
Conjugate that Potentially Kills Cancer Cells
Selectively
Qiong Wei
Huazhong University of Science and Technology

Dejun Zhang
Huazhong University of Science and Technology

Anna Yao
Huazhong University of Science and Technology
See next page for additional authors

Follow this and additional works at: http://scholarscompass.vcu.edu/medc_pubs
Part of the Pharmacy and Pharmaceutical Sciences Commons
Copyright: © 2012 ZHOU et al. This is an open-access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
author and source are credited.

Downloaded from
http://scholarscompass.vcu.edu/medc_pubs/14

This Article is brought to you for free and open access by the Dept. of Medicinal Chemistry at VCU Scholars Compass. It has been accepted for
inclusion in Medicinal Chemistry Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact
libcompass@vcu.edu.

Authors

Qiong Wei, Dejun Zhang, Anna Yao, Liyi Mai, Zhiwei Zhang, and Qibing Zhou

This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/medc_pubs/14

Design, Synthesis, and In Vitro and In Vivo Biological
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Abstract
Thymidine kinases (TKs) have been considered one of the potential targets for anticancer therapeutic because of their
elevated expressions in cancer cells. However, nucleobase analogs targeting TKs have shown poor selective cytotoxicity in
cancer cells despite effective antiviral activity. 39-Deoxythymidine phenylquinoxaline conjugate (dT-QX) was designed as
a novel nucleobase analog to target TKs in cancer cells and block cell replication via conjugated DNA intercalating
quinoxaline moiety. In vitro cell screening showed that dT-QX selectively kills a variety of cancer cells including liver
carcinoma, breast adenocarcinoma and brain glioma cells; whereas it had a low cytotoxicity in normal cells such as normal
human liver cells. The anticancer activity of dT-QX was attributed to its selective inhibition of DNA synthesis resulting in
extensive mitochondrial superoxide stress in cancer cells. We demonstrate that covalent linkage with 39-deoxythymidine
uniquely directed cytotoxic phenylquinoxaline moiety more toward cancer cells than normal cells. Preliminary mouse study
with subcutaneous liver tumor model showed that dT-QX effectively inhibited the growth of tumors. dT-QX is the first
molecule of its kind with highly amendable constituents that exhibits this selective cytotoxicity in cancer cells.
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thymidine kinase followed by nucleobase analogs has been
investigated in liver cancer patients with limited effects achieved
[15]. This is likely due to that TKs oriented nucleobase analogs
such as AZT are quickly removed by nucleobase repair processes
after they are incorporated in the DNA synthesis of cancer cells via
the thymidine salvage pathway [16–18]. 5-Fluorouracil, another
thymine analog, is a dihyrofolate reductase inhibitor and directly
causes cytotoxicity in normal hepatocytes [3,19]. Therefore,
alternative design of more effective nucleobase analogs targeting
TKs is needed.
We report here a novel 39-deoxythymidine phenylquinoxaline
conjugate (dT-QX, Figure 1) that selectively kills a variety of
cancer cells, but not normal hepatocytes. Structurally, dT-QX is
a 39-triazole-39-deoxythymidine linked to a DNA intercalating
quinoxaline moiety. dT-QX was designed to target the thymidine
salvage pathway based on the fact that 39-triazole thymidine
derivatives are recognized by human thymine kinases [20,21]. The
purpose of adding the quinoxaline moiety into dT-QX structure
was to block cellular removal of thymidine analogs [16–18] via
DNA intercalation in the DNA synthesis of cancer cells, because
quinoxaline moiety is a known DNA intercalator [22]. In addition,
the quinoxaline structure can be conveniently synthesized by one
step condensation of a diketone compound 1 [23] and an ortho-

Introduction
With cancers being the leading cause of death world-wide,
developing safe and effective anticancer agents remains in urgent
need. Molecularly targeted therapy has been the recent focus for
anticancer drug development, as seen in the example of Sorafenib
[1,2]. Sorafenib is a multi-tyrosine kinase inhibitor that can
potentially minimize adverse effects such as hepatotoxicity caused
by other anticancer drugs including 5-fluorouracil and doxorubicin [3,4]. Similar to tyrosine kinases, thymidine kinases (TKs) have
been considered another potential anticancer target [5–8]. TKs
are the first phosphorylating enzymes in the thymidine salvage
pathway converting thymidine to its 59-phosphate form for DNA
synthesis. In normal mammalian cells, cytosolic TKs are only
present at a low level in the S phase of cells; whereas elevated level
of TKs have been observed in virus infected cells and rapidly
proliferating cancer cells [5–8], e.g., lung tumors and breast cancer
tissues [9,10].
Nucleobase analogs targeting TKs such as AZT and acyclovir
have been shown effective antiviral activity [11,12]. However,
poor cancer-selectivity and strong side effects have been associated
with nucleobase analogs including neutron capture agent 5thymidine boron conjugate and radioisotopic iodinated deoxyuridine [13,14]. Recently, a combination therapy using predelivered
PLOS ONE | www.plosone.org

1

December 2012 | Volume 7 | Issue 12 | e52199

A Thymidine Conjugate Kills Cancer Cells

24.5 ppm (Figure S1); HRMS calcd for C9H15BrNO
[M+H]+232.0337 and [M+2+H]+234.0316, found 232.0324 and
234.0413.

phenylenediamine (Figure 1). More importantly, the quinoxaline
structure is highly amendable for chemical modifications with
a variety of substituents for advanced structure activity study to
optimize the potential biological activity. The anticancer activity
of dT-QX was then evaluated using a panel of cancer cells. The
effects of dT-QX on inhibiting DNA synthesis and inducing
cellular oxidative stress were also investigated. Finally, the
inhibition of tumor growth by dT-QX was assessed in mice
bearing subcutaneous liver tumors.

N-(Prop-2-ynyl)-6-(4b,8,8-trimethyl-9,10-dioxo4b,5,6,7,8,8a,9,10-octahydrophenanthren-2yloxy)hexanamide (3). To a solution of 2 (390 mg, 1.68 mmol)

in dry DMF (50 mL) were added 1 (355 mg, 1.30 mmol) and
potassium carbonate (1.8 g, 13.0 mmol). The reaction mixture
was stirred under N2 for 16 h at room temperature and then
acidified to pH 5 with 5 N HCl. The resulting solution was
extracted with CH2Cl2 (150 mL63). The organic layers were
collected, washed with brine (250 mL), dried with MgSO4 and
concentrated. A flash chromatographic separation (0–40% EtOAc
in hexane) afforded 3 as a yellow oil (320 mg, 0.76 mmol) in 58%
yield. 1H NMR (CDCl3, 400 MHz): d = 7.53 (d, 4J(H,H) = 2.9 Hz,
1H; CH), 7.35 (d, 3J(H,H) = 8.8 Hz, 1H; CH), 7.21 (dd,
3
J(H,H) = 8.7 Hz, 4J(H,H) = 2.7 Hz, 1H; CH), 5.94 (br s, 1H;
NH), 4.04 (dd, 3J(H,H) = 5.3 Hz, 4J(H,H) = 2.6 Hz, 2H; CH2),
4.00 (t, 3J(H,H) = 6.4 Hz, 2H; CH2), 2.65 (s, 1H; CH), 2.53 (d,
3
J(H,H) = 14.3 Hz, 1H, CH), 2.24 (t, 3J(H,H) = 7.6 Hz, 2H; CH2),
2.21 (d, 4J(H,H) = 2.5 Hz, 1H; CH), 1.82-1.70 (m, 4H; 2CH2),
1.56-1.31(m, 7H; 3CH2, CH), 1.18 (s, 3H; CH3), 0.95 (s, 3H;
CH3), 0.38 ppm (s, 3H; CH3); 13C NMR (CDCl3, 100.6 MHz):
d = 199.0, 181.3, 172.4, 158.1, 142.6, 134.6, 126.1, 124.2, 112.6,
71.7, 68.9, 68.1, 41.9, 39.2, 39.0, 36.3, 36.3, 35.5, 31.4, 29.7, 29.2,
28.9, 25.7, 25.2, 24.3, 18.8 ppm (Figure S2); HRMS calcd for
C26H34NO4 [M+H]+424.2488, found 424.2487.

Materials and Methods
Synthesis
All chemicals were purchased from Sigma-Aldrich (WI, USA),
J&K Scientific Ltd. (Beijing, China), or Sinopharm Chemical
Reagent Co., Ltd (Shanghai, China) and used without further
purification. NMR spectra were recorded with Bruker Avance-400
NMR spectrometer (Madison, WI, USA). Abbreviations used for
the split patterns of proton NMR signals are: singlet (s), doublet (d),
triplet (t), quartet (q), quintet (qui), multiplet (m) and broad signal
(br). Electrospray ionization mass spectroscopy (ESI-MS) analysis
was carried out with a Thermo Fisher TSQ Quantum Max Triple
Stage Quadrupole mass spectrometer (MA, USA). Compound 1
was obtained as previously reported [23].
6-Bromo-N-(prop-2-ynyl)hexanamide (2). To a solution of
6-bromohexanoic acid (694 mg, 3.56 mmol) in dry CH2Cl2
(50 mL) were added propargylamine hydrochloride (300 mg,
3.28 mmol), triethylamine (332 mg, 3.28 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (630 mg,
3.28mmol). The reaction mixture was stirred under N2 for 16 h at
room temperature. The resulting solution was extracted with
CH2Cl2 (150 mL63). The organic layers were collected, washed
with brine (250 mL), dried with MgSO4 and concentrated. A flash
chromatographic separation (0–40% EtOAc in hexane) afforded 2
as 1:1 syn/anti-amide mixture as a colorless oil (390 mg,
1.68 mmol) in 51% yield. 1H NMR (CDCl3, 400 MHz, 1:1
syn/anti): d = 5.71 (br s, 1H; NH), 4.05 (dd, 3J(H,H) = 5.2 Hz,
4
J(H,H) = 2.5 Hz, 2H; CH2), 3.53 (t, 3J(H,H) = 6.6 Hz, 1H;
0.5CH2), 3.40 (t, 3J(H,H) = 6.7 Hz, 1H; 0.5CH2), 2.24-2.19 (m,
3H; CH, CH2), 1.87(qui, 3J(H,H) = 7.2 Hz, 1H; 0.5CH2), 1.79
3
(qui,
J(H,H) = 7.0 Hz,
1H;
0.5CH2),
1.67
(qui,
3
J(H,H) = 7.52 Hz, 2H; CH2), 1.50-1.41 ppm (m, 2H; CH2);
13
C NMR (CDCl3, 100.6 MHz, 1:1 syn/anti): d = 172.3, 172.2,
79.5, 71.6, 44.8, 36.1, 36.1, 33.5, 32.4, 32.2, 29.1, 27.7, 26.4, 24.7,

N-(Prop-2-ynyl)-6-(4b,8,8-trimethyl-4b,5,6,7,8,8ahexahydrodibenzo[a,c]phenazin-2-yloxy)-hexanamide
(4). To a solution of 3 (320 mg, 0.76 mmol) in toluene (25 mL)

were added o-phenylenediamine (103 mg, 0.95 mmol) and silica
gel (300 mg). The reaction mixture was refluxed under N2 for 18 h
and then concentrated. A flash chromatographic separation (0–
40% EtOAc in hexane) afforded 5 as a yellow solid (230 mg,
0.46 mmol) in 61% yield. 1H NMR (CDCl3, 400 MHz): d = 8.098.07 (m, 3H; 3CH), 7.73-7.67 (m, 2H; 2CH), 7.30 (d,
3
J(H,H) = 8.8 Hz, 1H; CH), 7.02 (dd, 3J(H,H) = 8.4 Hz,
4
J(H,H) = 2.8 Hz, 1H; CH), 5.71 (br s, 1H; NH), 4.14-4.06 (m,
4H; 2CH2), 2.88 (s, 1H; CH), 2.56 (br d, 3J(H,H) = 14 Hz, 1H,
CH), 2.28-2.23 (m, 3H; CH2, CH), 1.89-1.73 (m, 4H; 2CH2),
1.59-1.47 (m, 7H; 3CH2, CH), 1.02 (s, 3H; CH3), 0.99 (s, 3H;
CH3), 0.16 ppm (s, 3H; CH3); 13C NMR (CDCl3, 100.6 MHz):
d = 172.4, 158.0, 154.8, 148.4, 141.9, 141.3, 137.6, 134.8, 129.2,
129.1, 129.0, 128.6, 125.0, 118.1, 111.2, 79.6, 71.6, 67.7, 59.7,

Figure 1. Structural design of dT-QX.
doi:10.1371/journal.pone.0052199.g001
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Figure 2. Synthesis of dT-QX and reference compound Pip-QX.
doi:10.1371/journal.pone.0052199.g002

To a solution of 1 (650 mg, 2.39 mmol) in
DMF (30 mL) were added 4-methyl-1-piperazinecarbonyl chloride hydrochloride (630 mg, 3.16 mmol) and potassium carbonate
(3.4 g, 24 mmol). The reaction mixture was stirred under N2 for
18 h and then acidified to pH 5 with 5 N HCl. The resulting
solution was extracted with CH2Cl2 (150 mL63). The organic
layers were collected, washed with brine (250 mL), dried with
MgSO4 and concentrated. A flash chromatographic separation (0–
25% EtOAc in hexane) afforded 5 as a yellow oil (730 mg,
1.83 mmol) in 77% yield. 1H NMR (CDCl3, 400 MHz): d = 7.86
(s, 1H; CH), 7.49 (s, 2H; 2CH), 3.71 (br s, 2H; CH2), 3.61 (br s,
2H; CH2), 2.69 (s, 1H; CH), 2.58 (d, 3J(H,H) = 13.3 Hz, 1H; CH),
2.49 (br s, 4H; 2CH2), 2.37 (s, 3H; CH3), 1.47-1.42 (m, 5H; 2CH2,
CH), 1.23 (s, 3H; CH3), 0.98 (s, 3H; CH3), 0.41 ppm (s, 3H; CH3);
13
C NMR (CDCl3, 100.6 MHz): d 198.2, 180.6, 152.5, 149.8,
147.4, 134.6, 129.4, 126.3, 122.5, 68.7, 53.7, 53.6, 41.7, 39.5,
38.7, 36.2, 36.1, 35.5, 31.2, 26.9, 24.2, 24.2, 18.7 ppm (Figure S6);
HRMS calcd for C23H31N2O4 [M+H]+299.2284, found
299.2294.

42.0, 37.3, 36.3, 36.1, 36.0, 34.8, 31.5, 29.2, 29.1, 25.8, 25.3, 22.1,
19.0 ppm (Figure S3); HRMS calcd for C32H38N3O2
[M+H]+496.2964, found 496.2964.

carboxylate (5).

N-((1-(2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1,2,3triazol-4-yl)methyl)-6-(4b,8,8-trimethyl-4b,5,6,7,8,8ahexahydrodibenzo[a,c]phenazin-2-yloxy)hexanamide (dTQX). To a solution of 4 (100 mg, 0.2 mmol) in 5 mL DMF

and 10 mL CH2Cl2 were added 39-azido-39-deoxythymidine
(54 mg, 0.20 mmol) and an aqueous solution of sodium ascorbate
(40 mM, 15 mL). The reaction mixture was purged with N2 for
10 min, and CuSO4?5H2O (8 mg, 0.03 mmol) was added. The
reaction mixture was then stirred under N2 at room temperature
for 12 h. The resulting solution was extracted with CH2Cl2
(150 mL63). The organic layers were collected, washed with brine
(200 mL), dried with MgSO4 and concentrated. A flash chromatographic separation (0–7% MeOH in CH2Cl2) afforded dTQX as a white solid (114 mg, 0.15 mmol) in 75% yield. 1H NMR
(DMSO-d6, 400 MHz): d = 11.35 (s, 1H; OH), 8.34 (t,
3
J(H,H) = 5.5 Hz, 1H; CH), 8.14-8.11 (m, 2H; 2CH), 8.06-8.04
(m, 1H; CH), 7.96 (d, 4J(H,H) = 2.8 Hz, 1H; CH), 7.79 (m, 3H;
2CH, NH), 7.39 (d, 3J(H,H) = 8.7 Hz, 1H; CH), 7.11 (dd,
3
J(H,H) = 8.5 Hz, 4J(H,H) = 2.8 Hz, 1H; CH), 6.40 (t,
3
J(H,H) = 6.6 Hz, 1H; CH), 5.36-5.33 (m, 1H; CH), 5.28 (t,
3
J(H,H) = 5.2 Hz, 1H; NH), 4.31 (d, 3J(H,H) = 5.5 Hz, 2H; CH2),
4.18 (m, 1H; CH), 4.06 (t, 3J(H,H) = 6.4 Hz, 2H; CH2), 3.67-3.60
(m, 2H; CH2), 2.85 (s, 1H; CH), 2.67-2.57 (m, 2H; CH2), 2.16 (t,
3
J(H,H) = 7.4 Hz, 2H; CH2), 1.79-1.62 (m, 5H; CH3, CH2), 1.561.43 (m, 10H; 5CH2), 0.93 (s, 3H; CH3), 0.91 (s, 3H; CH3),
0.07 ppm (s, 3H; CH3); 13C NMR (DMSO-d6, 100.6 MHz):
d = 172.0, 163.6, 157.4, 154.2, 150.4, 147.5, 145.2, 141.1, 140.9,
137.1, 136.1, 134.1, 129.5, 129.4, 128.9, 128.4, 125.3, 122.4,
117.7, 110.8, 109.5, 84.4, 83.8, 67.4, 60.6, 59.0, 58.5, 41.2, 37.0,
36.8, 35.5, 35.1, 34.9, 34.4, 34.0, 31.3, 28.5, 25.2, 24.9, 21.6, 18.5,
12.2 ppm; HRMS calcd for C42H51N8O6 [M+H]+763.3932,
found 763.3959 (Figures S4 and S5).

4b,8,8-Trimethyl-4b,5,6,7,8,8ahexahydrodibenzo[a,c]phenazin-2-yl 4-methylpiperazine-1carboxylate (Pip-QX). To a solution of 5 (330 mg, 0.83 mmol)

in toluene (25 mL) were added o-phenylenediamine (100 mg,
0.92 mmol) and silica gel (300 mg). The reaction mixture was
refluxed under N2 for 18 h and then concentrated. A flash
chromatographic separation (0–3% MeOH in CH2Cl2) afforded
Pip-QX as a yellow oil (310 mg, 0.66 mmol) in 79% yield. 1H
NMR (DMSO-d6, 400 MHz): d = 8.14-8.05 (m, 3H; 3CH), 7.817.79 (m, 2H; 2CH), 7.49 (d, 3J(H,H) = 8.4 Hz, 1H; CH), 7.29 (dd,
3
J(H,H) = 8.4 Hz, 4J(H,H) = 2.4 Hz, 1H; CH), 3.63 (br s, 2H;
CH2), 3.46 (br s, 2H; CH2), 2.88 (s, 1H; CH), 2.58 (m, 1H; CH2),
2.38 (br s, 4H; 2CH2), 2.16 (s, 3H; CH3), 1.51-1.38 (m, 5H; 2CH2,
CH), 0.96 (s, 3H; CH3), 0.90 (s, 3H; CH3), 0.06 ppm (s, 3H; CH3);
13
C NMR (DMSO-d6, 100.6 MHz): d = 154.4, 153.3, 150.5,
147.5, 142.3, 141.6, 134.7, 130.2, 130.2,129.4, 129.0, 125.7,
125.2, 119.3, 58.9, 54.7, 54.6, 46.2, 44.6, 44.0, 41.6, 37.7, 36.1,
35.4, 34.7, 31.8, 22.2, 19.0 ppm (Figure S7); HRMS calcd for
C29H35N4O2 [M+H]+471.2760, found 471.2767.

4b,8,8-Trimethyl-9,10-dioxo-4b,5,6,7,8,8a,9,10octahydrophenanthren-2-yl
4-methyl-piperazine-1PLOS ONE | www.plosone.org
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Figure 3. Selective killing of cancer cell lines over a normal human liver cell line. A panel of cancer cell lines (black color) and a normal liver
hepatocyte cell line (red color) were treated with a) dT-QX; b) Pip-QX; c) AZT; d) Pip-QX plus AZT and e) doxorubicin, respectively. Cell viability was
assessed after 72 h incubation by MTT assay. The percent viability was calculated and fitted with dose-response curves using GraphPad Prism
software. All treatments were conducted in triplicates and repeated at least three times.
doi:10.1371/journal.pone.0052199.g003

tion of 0, 0.1, 1, 10, 20, 50, 100, or 200 mM with total DMSO less
than 0.2%. Doxorubicin was used as a comparison at a final
concentration of 0.05, 0.1, 0.2, 0.5, 1.0 or 2.0 mM. After 72 h,
MTT assay was carried out as reported [23]. The cell viability of
each treatment was plotted with GraphPad Prism program, and
IC50 values were obtained using sigmoidal dose-response analysis
provided by the software (version 4.00, GraphPad Software, CA,
USA).
Anti-BrdU fluorescence assay. Hep3B, HepG2 or HL7702 cells (50,000 per well) were seeded in the growth media
overnight on 48-well plates and treated with 0, 10 or 50 mM dTQX for 5 h. Anti-BrdU assay was carried out according to the
manufacturer’s recommendation (BD Biosciences, NJ, USA).
Briefly, BrdU solution (0.1 mg/mL) was added to each well, and
cells were incubated at 37uC for 3 h. Cell medium was removed
and cells were fixed with 3.7% formaldehyde in PBS. Cells were
permeablized with 0.1% triton-100 in PBS and blocked with 3%
FBS in PBS solution. Cellular DNA was denatured by DNaseI
(0.3 mg/mL) in PBS solution. The incorporated BrdU was stained
with Alexa FluorH488 anti-BrdU monoclonal antibody (BD
Biosciences, NJ, USA). The nuclei were counter-stained with
Hoechst 33342 solution. Cell images of each treatment were

Biological Studies
The animal protocol was approved by the Reviewing Committee of College of Life Science and Technology at Huazhong
University of Science and Technology. Cancer cell lines HepG2,
Hep3B, MCF-7 and C6 were obtained from ATCC (VA, USA).
Human liver cells HL-7702 and murine liver cancer cells H22
were from Shanghai Institute of Life Science Cell Culture Center
(Shanghai, China). Cells were maintained in high glucose DMEM
or RPMI-1640 medium (Invitrogen, CA, USA) supplemented with
10% heat-inactivated fetal bovine serum (FBS), 25 mM HEPES,
2 mM L-glutamine, 0.1 mM nonessential amino acids, 1.0 mM
sodium pyruvate, 50 U/mL penicillin, and 50 mg/mL streptomycin at 37uC and 5% CO2. Stock solutions of dT-QX, Pip-QX or
AZT were prepared in DMSO, and doxorubicin hydrochloride
salt was directly dissolved in water. All biological chemicals were
obtained from Sigma Aldrich (WI, USA) unless specified otherwise. All of the experiments were independently repeated at least
three times.
Cell viability MTT assay. Cells (5,000 per well) were seeded
on 96-well plates in growth media overnight before each treatment
in triplicates. dT-QX, Pip-QX or AZT was at a final concentra-
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Figure 4. Fluorescence images of anti-BrdU assay of cell division and proliferation after compound treatment. BrdU assay was carried
out after cells treated with compounds for 5 h. The incorporated BrdU was stained with anti-BrdU Alexa FluorH488 monoclonal antibody (green color)
with cell nuclei counter-stained with Hoechst 33342 (blue color). a) BrdU incorporation in HL-7702, HepG2 or Hep3B cells treated with DMSO or dTQX; b) BrdU incorporation inHep3B cells treated with DMSO, AZT or Pip-QX.
doi:10.1371/journal.pone.0052199.g004

removed. A solution of MitoSOX Red mitochondrial superoxide
indicator (Invitrogen, CA, USA) in PBS was added and incubated
at 37uC for 20 min. Cells were then washed once with PBS and
counter-stained with Hoechst 33342 solution. Fluorescent images
were captured with Olympus IX71 inverted microscope under
appropriate lights. The study with 100 mM Mn(III) tetrakis(1methyl-4-pyridyl)porphyrin tetratosylate hydroxide (MnTmPyP,

captured with Olympus IX71 inverted microscope equipped with
a digital camera under appropriate lights. The impacts of Pip-QX
and AZT on the DNA synthesis in Hep3B were assessed similarly
as described above.
Fluorescence study of mitochondrial superoxide
production. Hep3B or HL-7702 cells (50,000 per well) were

seeded in the growth media overnight on 48-well plates. Cells were
treated with 0 or 50 mM dT-QX for 8 h and then medium was

Figure 5. Fluorescence staining of mitochondrial superoxide production upon treatment. Cancer cell line Hep3B or normal HL-7702 cells
were treated with DMSO or 50 mM dT-QX for 8 h. The level of mitochondrial superoxide was detected with MitoSOX mitochondrial superoxide
indicator (red color). Cell nuclei were counter-stained with Hoechst dye (blue color).
doi:10.1371/journal.pone.0052199.g005

PLOS ONE | www.plosone.org
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Figure 6. Growth inhibition of subcutaneous tumors by dT-QX in mice. Subcutaneous tumor was established by injecting H22 cell at the
lower back of BALB/c mice subcutaneously (36106 cells per mouse). After tumors reached an average size of (868 mm, 340 mm3), mice (3 per group)
were injected with 100 mL of saline (with 0.1% DMSO), AZT (50 mM in sterile PBS with 0.1% DMSO) or dT-QX (50 mM in sterile PBS with 0.1% DMSO) on
the tumor site on day 1 and day 7. The tumor growth and body weight were monitored daily. On day 12 following the first injection, all mice were
euthanized and images of tumors were recorded. a) Growth profile of average tumor size over the 12-day treatments of each treatment group; b)
Images of tumors of each treatment group on day 12 after first injection.
doi:10.1371/journal.pone.0052199.g006

EMD Chemicals, Inc., USA) as a positive control on Hep3B cells
was carried similarly.
Subcutaneous liver tumor study in mice. Murine liver
cancer cells H22 were initially maintained in the RPMI-1640
growth medium and then grow in the BALB/c mice (Hubei
Provincial Laboratory Animal Center, China) intraperitoneally.
Mice were euthanized after 4 days and H22 cells were harvested
with PBS solution. H22 cells were washed once with sterile PBS
and were injected subcutaneously (3x106 cells per mouse) at the
lower back of naive BALB/c mice. Once tumors reached an
average size of (8x8 mm, 340 mm3), nine mice were randomly
divided into three groups (3 per group) and injected with 100 mL
of saline (with 0.1% DMSO), AZT (50 mM in sterile PBS with
0.1% DMSO) or dT-QX (50 mM in sterile PBS with 0.1%
DMSO) on the tumor site on day 1 and day 7. The tumor growth
and body weight were monitored daily. On day 12 followed the
first injection, all mice were euthanized and images of tumors were
recorded. Statistic analysis (one way ANOVA with Tukey’s
multiple comparison test) of the treatments was performed using
GraphPad Prism software.

The biological activity of dT-QX was first assessed using cell
viability assay on a panel of cancer cell lines including human
liver carcinoma HepG2 and Hep3B, mouse liver carcinoma
H22, breast adenocarcinoma MCF-7, and rat brain glioma C6
cells. Human liver HL-7702 cell line was used as a representative
of normal cells in the study. HL-7702 cells are transformed
human normal hepatocytes with low expression of cancer
markers [24]. Treatment of HL-7702 with dT-QX did not
resulted in any significant cytotoxicity at concentrations as high
as 200 mM (Figure 3a). The EC50 of dT-QX on all cancer cells
was found to range from 6.6 to 42.1 mM. The most pronounced
cytotoxicity was observed on human hepatocellular carcinoma
Hep3B cells with more than 80% cell death at 20 mM, followed
by breast adenoma MCF-7 and brain glioma C6 cells. In stark
contrast, Pip-QX non-selectively killed all cell lines including
HL-7702 at 50 mM (Figure 3b). The second reference
compound, AZT as a 39-deoxythymidine analog, was found to
exhibit low cytotoxicity against these cell lines (Figure 3c), while
co-treatment of AZT plus Pip-QX also non-selectively killed all
cell lines (Figure 3d), similar to that of Pip-QX treatment alone.
These results suggested that the selective killing of cancer cells
over normal liver cells by dT-QX was due to the unique
covalent conjugation of cytotoxic phenylquinoxaline moiety with
39-deoxythymidine. In comparison, the anticancer drug doxorubicin was found highly toxic to all these cells. In fact,
doxorubicin was even more toxic toward normal liver 7702 cells
than liver cancer Hep3B or H22 cells at concentrations above
0.5 mM (Figure 3e).
To further understand the selective cytotoxicity of dT-QX
towards cancer cells, we first investigated cell proliferation using
anti-BrdU fluorescence assay. BrdU (5-bromo-39-deoxyuridine) is
a thymidine analog that is incorporated into cell genome as it
replicates [25]. Thus, the level of BrdU in cell nucleus reflects the
level of cell division and proliferation. Considering the above cell
viability results, human HL-7702, HepG2 and Hep3B cells were
investigated as representatives of normal and cancer cells. The
anti-BrdU assay was carried out at 5 h after dT-QX treatment to
allow enough accumulation of compound in cells and to determine
its impact on cellular DNA synthesis. The level of BrdU in cell
nuclei was measured using a fluorescent anti-BrdU conjugate [25]
(green color) with cell nuclei counter-stained by Hoechst 33342
(blue color) as shown in Figure 4.

Results and Discussion
Synthesis of dT-QX was achieved by coupling AZT with
phenylquinoxaline 4 via copper(I)-catalyzed click reaction
(Figure 2). Intermediate 3 was obtained from nucleophilic
substitution of bromoalkyne 2 with oxidized terpenone 1.
Phenylquinoxaline 4 was obtained by condensation with odiaminobenzene and silica gel under reflux in toluene, which
was much better than acetonitrile, DMF or ethanol. The
conjugation of AZT with phenylquinoxaline 4 to dT-QX was
accomplished in 75% yield using the in situ reduction of copper(II)
by ascorbate [20,21]. Phenylquinoxaline 4, a reference molecule,
was found to be poorly soluble in 1% DMSO aqueous solution
and hence was modified to a N-methylpiperazine derivative PipQX as shown in Figure 2. Pip-QX was synthesized in a manner
similar to dT-QX via conversion of 1 to the piperazine derivative
5, followed by condensation with o-diaminobenzene in an overall
yield of 61%. Pip-QX served as one of reference compounds in
following biological studies. Multiple batches of dT-QX and
control compounds were synthesized, and all the batches
performed consistently not only in chemistry but also in biological
studies.
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murine H22 liver cancer cells [29]. Tumors were allowed to reach
an average size of 8.868.8 mm. The relative low solubility of dTQX in PBS solution limited the route of administration to be intratumor injections. Thus, AZT or dT-QX (100 mL650 mM each)
was injected directly into tumors on day 1 and day 7. Regardless of
treatments, neither mice died nor was there a significant body
weight loss observed during the 12-day study. The tumor growth
profile over 12 days after the first injection is shown in Figure 6a.
Tumors in mice treated with AZT grew rapidly, similar to those of
negative control (saline); whereas the growth of tumors was
significantly inhibited in dT-QX treated mice (Figure 6a). On day
12 after the first injection, the sizes of tumors in mice injected with
dT-QX were clearly smaller than those with AZT or saline
(Figure 6b). Statistic analysis also confirmed that the treatment of
dT-QX was significantly different from the other two (P,0.01).
These results suggested that intra-tumor injection of dT-QX at
a low dosage (equivalent to 0.13 mg/kg per mouse) was quite
effective at inhibiting the growth of subcutaneous tumors in
a mouse model.
In conclusion, dT-QX as a novel thymidine analog exhibited
an excellent selective cytotoxicity toward a variety of cancer
cells but not on normal human liver HL-7702 cells. The
selectivity was achieved through selective inhibition of cellular
DNA synthesis by dT-QX, resulting in mitochondrial superoxide stress which may lead to mitochondrial dysfunction. The
covalent linkage with 39-deoxythymidine uniquely directed the
cytotoxicity of phenylquinoxaline moiety more toward cancer
cells than normal liver cells. Preliminary in vivo study also
demonstrates that dT-QX could be a potential drug candidate
for anti-cancer agents. dT-QX is the first molecule of its kind
that exhibits this high selective cytotoxicity and excellent in vivo
potency. Considering the highly amendable structural constituents for better anti-cancer activity and low hepatotoxicity, the
potential of dT-QX as a lead compound for anti-cancer drug
development is therefore very promising.

In normal human HL-7702 cells, treatments of DMSO and dTQX resulted in similar levels of BrdU incorporation in cell nuclei,
which indicated the presence of dT-QX did not interfere with cell
division and proliferation. However, significant loss of green
fluorescence was observed in cancerous HepG2 and Hep3B cells
with dT-QX treatment as compared to that of DMSO control
(Figure 4a). These results indicated that dT-QX selectively
inhibited cellular DNA synthesis of HepG2 and Hep3B cells at
the early stage of treatment resulting in selective killing both of
cancer cells. The inhibition of BrdU incorporation was much more
pronounced on Hep3B cells with the complete loss of green
fluorescence in cell nuclei (Figure 4a). This was consistent with cell
viability results that dT-QX was more effective at killing Hep3B
than HepG2 cells. The more pronounced cytotoxicity on Hep3B
cell than HepG2 may be due to the fact that Hep3B is originated
from hepatitis B infection [26].
To elucidate which chemophore of dT-QX was responsible for
the inhibition of DNA synthesis, the anti-BrdU fluorescence assay
was carried out with AZT or Pip-QX on Hep3B cells (Figure 4b).
Treatment of AZT resulted in no significant inhibition of DNA
synthesis, while Pip-QX significantly inhibited the DNA synthesis
in cells, similar to that of dT-QX, indicating phenylquaxinoline
chemophore was responsible for the inhibition of DNA synthesis
observed. In combination with cell viability results, it suggested
that conjugation with 39-deoxythymidine uniquely modified the
cytotoxic phenylquinoxaline chemophore to make it more
selective toward cancer cells than normal hepatocytes. These
results also confirmed that conjugating the quinoxaline moiety
with 39-triazole-39-deoxythymine led to selectively targeting cancer
cells by blocking their DNA synthesis.
The selective inhibition of nuclear DNA synthesis by dT-QX in
cancer cells led to the hypothesis that dT-QX might selectively
inhibit the mitochondrial DNA synthesis and cause mitochondrial
dysfunction as well. Unfortunately, the anti-BrdU fluorescent assay
was not sensitive enough to observe such inhibition in cells.
Alternatively, mitochondrial dysfunction due to DNA depletion by
nucleoside analogs has been reported to occur concurrently with
elevated superoxide level in mitochondria after treatment for 4
days [27]. Therefore, the impact of dT-QX on the mitochondrial
function was assessed using a fluorescence based mitochondrial
superoxide imaging assay. Hep3B cells were investigated as the
representative of cancer cell model because of the pronounced
inhibition of DNA synthesis at early stage by dT-QX observed in
anti-BrdU assay (Figure 4a).
Significant red fluorescence indicative of superoxide production
was detected in Hep3B cells after treatment of 50 mM dT-QX for
8 h as compared to that DMSO (Figure 5). The cytosolic presence
of red staining of superoxide was confirmed by counter-staining
cell nuclei with a Hoechst dye. It was also found that treatment of
Hep3B cells with dT-QX for a shorter time such as 3 or 5 h did
not induce significant red fluorescence, suggesting the production
of mitochondrial superoxide was accumulative and was likely due
to the inhibition of cellular DNA synthesis. In addition, a positive
control with a Mn(III)-chelator acting as a NADPH/GSH:O22
oxidoreductase in cells [28] resulted in a similar level of red
fluorescence in Hep3B cells to that treated with dT-QX (see
Figure S8). In contrast, low background red fluorescence was
observed in human normal HL-7702 cells treated with dT-QX,
similar to that treated with DMSO (Figure 5). Thus, these results
suggested that dT-QX could cause mitochondrial dysfunction by
inducing mitochondrial superoxide stress in cancer cells following
the inhibition of DNA synthesis.
A preliminary in vivo antitumor study with dT-QX was carried
out in a mouse model. Subcutaneous tumors were established with
PLOS ONE | www.plosone.org

Supporting Information
Figure S1

NMR spectra of compound 2.

(TIF)
Figure S2

NMR spectra of compound 3.

(TIF)
Figure S3

NMR spectra of compound 4.

(TIF)
Figure S4

NMR spectra of compound dT-QX.

(TIF)
Figure S5

Electrospray mass analysis of dT-QX.

(TIF)
Figure S6

NMR spectra of compound 5.

(TIF)
Figure S7

NMR spectra of Pip-QX.

(TIF)
Figure S8 Levels of mitochondrial superoxide production in Hep3B cells upon MnTmPyP and/or dT-QX
treatment for 8 h. Fluorescent images of cells were captured
after staining with MitoSOX Red mitochondrial superoxide
indicator solution.
(TIF)
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